- Home
- BORR vs ANAB Comparison
BORR vs ANAB Comparison
Compare BORR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- ANAB
- Stock Information
- Founded
- BORR 2016
- ANAB 2005
- Country
- BORR Bermuda
- ANAB United States
- Employees
- BORR N/A
- ANAB N/A
- Industry
- BORR Oil & Gas Production
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- ANAB Health Care
- Exchange
- BORR Nasdaq
- ANAB Nasdaq
- Market Cap
- BORR 941.4M
- ANAB 759.5M
- IPO Year
- BORR 2019
- ANAB 2017
- Fundamental
- Price
- BORR $1.89
- ANAB $18.18
- Analyst Decision
- BORR Buy
- ANAB Buy
- Analyst Count
- BORR 1
- ANAB 10
- Target Price
- BORR $9.00
- ANAB $36.38
- AVG Volume (30 Days)
- BORR 5.9M
- ANAB 931.5K
- Earning Date
- BORR 05-22-2025
- ANAB 05-08-2025
- Dividend Yield
- BORR 4.14%
- ANAB N/A
- EPS Growth
- BORR 255.56
- ANAB N/A
- EPS
- BORR 0.32
- ANAB N/A
- Revenue
- BORR $1,010,600,000.00
- ANAB $91,280,000.00
- Revenue This Year
- BORR $8.35
- ANAB N/A
- Revenue Next Year
- BORR $6.39
- ANAB $70.85
- P/E Ratio
- BORR $6.28
- ANAB N/A
- Revenue Growth
- BORR 30.98
- ANAB 432.03
- 52 Week Low
- BORR $1.62
- ANAB $12.21
- 52 Week High
- BORR $7.26
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- BORR 39.70
- ANAB 52.58
- Support Level
- BORR $1.89
- ANAB $15.40
- Resistance Level
- BORR $2.08
- ANAB $18.09
- Average True Range (ATR)
- BORR 0.18
- ANAB 1.41
- MACD
- BORR 0.01
- ANAB -0.11
- Stochastic Oscillator
- BORR 37.50
- ANAB 58.60
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).